23rd Annual International Ultmann Chicago Lymphoma Symposium
April 10-11, 2026

DESCRIPTION

The 23rd International Ultmann Chicago Lymphoma Symposium (IUCLS) is a continuation of an annual conference dedicated solely to the science and clinical care of lymphoma. It has been organized to honor the achievements of Dr. John Ultmann, a pioneer in the treatment of lymphoma, who devoted his life to the understanding of this disease. He was particularly known for his work on the staging of Hodgkin lymphoma and the utility of staging as a guide for treatment.

The goal of this educational activity is to facilitate a forum for physicians, nurses, researchers, and other healthcare professionals to discuss biologic, diagnostic, and therapeutic aspects of Hodgkin and non-Hodgkin lymphoma.

This event gives opportunities for providers to explore vital information on clinical updates and research in order to ensure they are using the latest treatment options in their practice.

TARGET AUDIENCE

The target audience for this symposium is practicing oncologists, hematologists, advanced nurse practitioners, physician assistants, residents, fellows, nurses, pharmacists, and the other health professionals interested in the treatment and diagnosis of lymphoma.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

- Evaluate safety and efficacy results from clinical trials investigating approved and novel treatment strategies being studied in patients with indolent and aggressive subtypes of B-cell and T-cell non-Hodgkin lymphoma;
- Develop strategies to optimize the selection and sequencing of therapeutic approaches for patients with newly diagnosed and relapsed/refractory Hodgkin lymphoma;
- Assess multiple various patient and disease-related factors and their impact on therapeutic decisions for patients with newly diagnosed and previously treated CLL/SLL;
- Cultivate strategies to enhance patient, caregiver, and healthcare provider communication in order to enhance the outcomes and survival of patients with lymphoma.

ACCREDITATION AND CREDIT DESIGNATION

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicine and Bio Ascend LLC. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 12 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

University of Chicago Medicine is accredited as a provider of continuing nursing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Participants who successfully complete the entire activity and complete an evaluation form will earn 12 contact hours.

American Board of Internal Medicine MOC Part II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Other Participant Credit
Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for *AMA PRA Category 1 Credits*™ from organizations accredited by the ACCME, please consult your professional licensing board.

EDUCATIONAL GRANTS/COMMERCIAL SUPPORT

Educational grant funding has been generously provided by:
ADC Therapeutics
AstraZeneca
Genentech
Genmab
Pfizer

DISCLOSURE DECLARATIONS

As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, the University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

COURSE FACULTY

The following faculty and planners have disclosed that they have no relevant financial relationships with ACCME defined commercial interests in the past twelve months:

Carla Casulo, MD
Andrew Evens, DO, MBA, MSc
Nicole Gazdzik, DNP
Leo I. Gordon, MD
Meghan E. Gutierrez, BA
Kaitlin P. Kelly, PharmD, BCOP
Max F. Kelsten, MD
Tara A. McCabe, ANP-BC
Teresa Palomero, PhD
Allison Rosenthal, DO
Joanna C. Yang, MD, MPH

Sairah Ahmed, MD serves as a consultant for ADC Therapeutics, KITE/Gilead, Genmab, and Bristol Meyers Squibb, and receives institutional research funding from Nektar, Merck, Genmab, KITE/Gilead, Janssen, Bristol Meyers Squibb, and Caribou.

Juan P. Alderuccio, MD serves as a consultant for ADC Theraptuics, Novartis, Eli Lilly, AbbVie, Genmab, Natera, and Tanabe Pharma Corporation, and receives institutional research support from BeOne, ADC Therapeutics, and Genmab.

Ruemu Birhiray, MD serves on the speaker's bureau for Amgen Inc., Puma Biotechnology, Johnson & Johnson, GSK, Lilly USA, LLC, Exelixis, Inc., E.R. Squibb & Sons, LLC., AstraZeneca Pharmaceuticals LP,

Sanofi, Daiichi Sankyo, Stemline, Beigene, Genmab, AbbVie, Boehringer Ingelheim, and Blue Medicines, and on the advisory board for Novartis, Genmab, Pharmacosmos, Nuvation, and Genentech.

Joshua Brody, MD receives institutional research funding from Pfizer, BMS, Merck, Roche/Genentech, AstraZeneca, and ADC Therapeutics.

Kirk E. Cahill, MD serves on the advisory board for Eli Lilly.

Elijah P. Darnell, MD will discuss CD19 targeting therapy in CLL, both approved (Liso-cel) as well as investigational and/or off label use of therapies based on recent clinical trials.

Matthew S. Davids, MD, MMSc serves as a consultant for AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, BeiGene, Bristol-Myers Squibb, Eli Lilly, Galapagos, Genentech, Genmab, Janssen, Merck, MEI Pharma, Nuvalent, and Schrödinger, and receives institutional research support from Ascentage, AstraZeneca, and MEI Pharma. Dr. Davids plans to discuss the unapproved/investigational use of venetoclax, ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib, and obinutuzumab (in the context of clinical trials).

Timothy S. Fenske, MD serves as a consultant for AbbVie, Natera, Adaptive Biotechnologies, Pierre Fabre, and Ipsen, as an expert witness for Bayer, and as a speaker for Pfizer.

Nilanjan Ghosh, MD, PhD serves as a consultant for Genentech/Roche, BMS, AstraZeneca, AbbVie, Pfizer, Galapagos, Janssen, Ipsen, and Beigene, and received institutional research funding from Genentech/Roche, AstraZeneca, and AbbVie, and on the Data Safety Monitoring Committee for Merck. Dr. Ghosh plans to discuss the unapproved/investigational use of bispeciifc antibodies in frontline setting and they are approved for use in later lines of therapy.

Brian Hill, MD, PhD serves as a consultant and received institutional research funding from AbbVie, Genentech, AstraZeneca, BeOne, Pharmacyclics, Gilead, BMS, and Genmab. Dr. Hill plans to discuss investigational/unapproved use of approved products off label as part of investigations into potential new areas of use.

Boyu Hu, MD receives institutional research funding from Genentech, Morphosys AG, Caribou Biosciences, Newave, AstraZeneca, and Lyell Immunopharma. Although the relationship has ended, Dr. Hu served as consultant for KITE, Pfizer, BMS, ADC Therapeutics, Genentech, and BeOne, and received institutional research funding from Repare Therapeutics, Artiva Biotherapeutics, and CRISPR Therapeutics.
Dr. Hu plans to discuss the unapproved/investigational clinical trials in early stage Hodgkin lymphoma, specifically AHOD2131 (NCT05675410), which utilizes brentuximab vedotin and nivolumab in combination as the trial's experimental arms. Both brentuximab vedotin and nivolumab are FDA approved for the treatment of Hodgkin lymphoma in the relapsed setting, but they are not approved for the frontline treatment of early stage Hodgkin lymphoma as of yet.

Yasmin H. Karimi, MD served as a consultant for AbbVie, ADC Therapeutics, Merck, and Genentech-Roche, AstraZeneca, Genmab, Incyte, Pfizer, and Foresight Diagnostics.

Reem Karmali, MD, MSc serves on the speaker’s bureau for BeiOne, Bristol Meyers Squibb, and Astra Zeneca, on the advisory board for Astra Zeneca, BMS and Avencell, and as a consultant for Genmab and KITE/Gilead. Although the relationship has now ended, Dr. Karmali did serve on the speaker’s bureau for Ipsen.

Supreet Kaur, MD serves as a consultant for Genentech, an advisor for Novartis, and receives institutional research funding from AbbVie/Genmab.

Vaishalee P. Kenkre, MD receives institutional funding from Ipsen, Novartis, MEI Pharma, Inc., and Seattle Genetics.

Justin Kline, MD serves as an advisor for Natera, Merck, BMS, and Gilead.

Neha Mehta-Shah, MD serves as a consultant for Abbvie, as an advisor for Acrotech Biopharma, Autolus, and receives institutional research funding from Bristol Meyers Squibb, C4 Therapeutics, Celgene,Seagen, Secura Bio-Grant, Treeline Pharma, Yingli Pharmacauticals, Innate Pharmaceuticals, Roche/Genentech, Astra Zeneca, Daichi Sankyo, and Morphosys.

Reid W. Merryman, MD serves as an advisor Genmab, BMS, AbbVie, Ipsen, KITE, Pfizer, and AstraZeneca and receives institutional research funding from Genmab, BMS, AbbVie, Merck, and Genentech/Roche.

Peter Riedell, MD serves on the advisory board for BMS, Kite/Gilead, Novartis, AbbVie, Genmab, Genentech/Roche, BeiGene, and ADC Therapeutics, as a consultant for BMS, AbbVie, Genmab, Genentech/Roche, Pfizer, BeiGene, CVS Caremark, Janssen, and Pharmacyclics, receives speaker honorarium from Adaptive Biotechnologies, and receives institutional research funding from BMS, Kite/Gilead, Novartis, Genentech/Roche, CRISPR Therapeutics, Fate Therapeutics, Cellectis, and Cargo Therapeutics.

David A. Russler-Germain, MD, PhD serves as a consultant for Abbvie, Regeneron, and Tempus, and on the advisory board for Genentech and Ipsen.

Sarah C. Rutherford, MD serves as a consultant for Abbvie, Genmab, Ipsen, Incyte, Kite, Natera, and Pfizer.
Mazyar Shadman, MD, MPH serves as a consultant, on the advisory board, and on the steering committees, and data safety monitoring committee for AbbVie, Ascentage, Genentech, AstraZeneca, Genmab, Janssen, BeiGene/ BeOne Medicines, Bristol Myers Squibb, Morphosys/Incyte, Kite Pharma, Eli Lilly, Fate Therapeutics, Nurix, Merck, Pfizer, and Pierre Fabre, and received institutional research funding from Mustang Bio, Genentech, Beigene/BeOne, AstraZeneca, Genmab, Morphosys/Incyte, and Vincerx.

Nirav N. Shah, MD serves on the advisory board and as a consultant for Nurix, Gilead-Kite, BMS-Juno, Miltenyi Biomedicine, Lilly Oncology, Incyte, AbbVie, BeOne Medicines, Kite Pharma, AstraZeneca, Ipsen, Genentech, and Galapagos. Dr. Shah receives institutional research funding from Lilly Oncology, Genentech, and Miltenyi Biomedicine, serves as a speaker for Lilly Oncology and Miltenyi Biomedicine and on the scientific advisory board for Tundra Therapeutics.

Tanaya Shree, MD, PhD receives institutional research funding from AstraZeneca.

Austin J. Sim, MD, JD receives institutional research funding from Novartis.

Sonali Smith, MD serves as a consultant for Genmab, Genentech, Foresight Diagnostics, and Regeneron.

Girish Venkataraman, MD serves on the speaker's bureau for Recordati, Inc. and as a consultant for Amgen and AstraZeneca.

Nina D. Wagner-Johnston receives institutional research funding from Genentech, Merck, and BMS.

Michael E. Williams, MD, ScM receives institutional research funding from Janssen, serves as a consultant and on the advisory board for Abbvie and BeOne and on the advisory board for AstraZeneca.

The staff of the Center for Continuing Medical Education and BioAscend have disclosed that they have no relevant financial relationships with ACCME defined commercial interests.
All relevant financial relationships listed for these individuals have been mitigated.